Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Thoracic 3Gynecologic 3Plasma cell 2Head & Neck 2Genitourinary 2Endocrine 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 2Urogenital Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Dexamethasone 47Lenalidomide 31daratumumab 24Bortezomib 23pomalidomide 19carfilzomib 15Specimen Handling 15Cyclophosphamide 15Calcium Dobesilate 15Biopsy 15Magnetic Resonance Spectroscopy 11talquetamab 9isatuximab 9Melphalan 9iberdomide 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8fludarabine 7belantamab mafodotin 7selinexor 5X-Rays 5tocilizumab 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
aldesleukin × Plasma cell × 30 days × Clear all
NCT06904066 2026-06-05

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
86 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡